Page last updated: 2024-08-24

triazoles and Dyspepsia

triazoles has been researched along with Dyspepsia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V	1

Trials

1 trial(s) available for triazoles and Dyspepsia

Article	Year
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast cancer research : BCR, 2010, Volume: 12, Issue:2 Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug Therapy, Combination; Dyspepsia; Etidronic Acid; Female; Humans; Middle Aged; Nausea; Nitriles; Osteoporosis, Postmenopausal; Patient Dropouts; Prospective Studies; Risedronic Acid; Risk Factors; Time Factors; Treatment Outcome; Triazoles	2010

Article

Year

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.

Breast cancer research : BCR, 2010, Volume: 12, Issue:2

Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug Therapy, Combination; Dyspepsia; Etidronic Acid; Female; Humans; Middle Aged; Nausea; Nitriles; Osteoporosis, Postmenopausal; Patient Dropouts; Prospective Studies; Risedronic Acid; Risk Factors; Time Factors; Treatment Outcome; Triazoles

2010